WASHINGTON, April 10, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after market close, with a conference call to follow at 5 p.m. ET.
Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call.
An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call.
Upcoming Investor Events
Additionally, Evolent announced that its executive management team will participate in upcoming investor conferences.
A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website. Presentation webcast times will be posted on the website as they become available.
About Evolent
Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting https://ir.evolent.com.
Contacts:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.80 |
| Daily Change: | -0.04 -0.51 |
| Daily Volume: | 1,272,597 |
| Market Cap: | US$904.570M |
September 23, 2025 August 07, 2025 May 08, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
